Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
The Role of Apixaban in the Treatment of Heparin-Induced Thrombocytopenia
by
Daw, Hamed
, Khalid, Sidra
in
Anticoagulants
/ Case reports
/ Internal Medicine
/ Pulmonary embolisms
/ Side effects
/ Thrombocytopenia
/ Thrombosis
2017
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
The Role of Apixaban in the Treatment of Heparin-Induced Thrombocytopenia
by
Daw, Hamed
, Khalid, Sidra
in
Anticoagulants
/ Case reports
/ Internal Medicine
/ Pulmonary embolisms
/ Side effects
/ Thrombocytopenia
/ Thrombosis
2017
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
The Role of Apixaban in the Treatment of Heparin-Induced Thrombocytopenia
Journal Article
The Role of Apixaban in the Treatment of Heparin-Induced Thrombocytopenia
2017
Request Book From Autostore
and Choose the Collection Method
Overview
Heparin-induced thrombocytopenia (HIT) can present as arterial and venous thrombosis in adults who are treated with heparin. We present a case of a patient who developed HIT when she was treated for deep venous thrombosis (DVT) and pulmonary embolism with heparin. During the treatment with heparin and while being transitioned to warfarin, she developed arterial thrombosis. A work-up for HIT was sent, and it was positive. She was started on the argatroban drip and her platelet counts stabilized. Since her platelet counts remained stable and were not increasing for three weeks, we decided to transition the patient to an oral anticoagulant. She was started on apixaban, a novel oral anticoagulant (NOAC), and her platelet counts remained stable. Therefore, through this case, we highlight the importance of platelet counts remaining stable when a patient with HIT is treated with apixaban.
Publisher
Springer Nature B.V,Cureus
Subject
This website uses cookies to ensure you get the best experience on our website.